Novo Nordisk is waging a multi-front campaign to defend its GLP-1 empire, but the clock is ticking louder than any courtroom gavel. The Danish drugmaker has filed two separate lawsuits — one against Eli Lilly and another against Hims & Hers — while simultaneously rolling out a direct-to-consumer subscription model for Wegovy, all as the first generic semaglutide in a G7 nation threatens to reset pricing dynamics across developed markets.
The legal battle with Eli Lilly, initiated on July 21, centers on television advertisements that Novo Nordisk claims make unfair comparisons between Zepbound and Wegovy. The complaint alleges that Lilly relies on outdated clinical data and contrasts low Wegovy doses against the highest approved Zepbound dosage. Novo Nordisk contends that newer studies on high-dose Wegovy demonstrate comparable efficacy, and is seeking a permanent injunction against the ads plus unspecified damages. Lilly has rejected the allegations and vowed to contest the suit. The earlier February 9 action against Hims & Hers targets compounded semaglutide products, which Novo Nordisk argues raise purity and dosing concerns flagged by the FDA. Hims & Hers shares tumbled roughly 16 percent after the filing became public.
That legal aggression extends beyond US borders. In South Africa, a court recently barred the provider iDexis from manufacturing compounded semaglutide at Novo Nordisk’s request, and the local health authority SAHPRA subsequently ordered a recall of those products. The moves signal a coordinated global strategy to protect the company’s intellectual property and market position.
Yet the most existential threat may come from a different direction entirely. Canada’s health regulator approved Svemia in July 2026 as the first generic semaglutide in any G7 country, creating a precedent that could accelerate generic entry in other wealthy nations. Novo Nordisk’s patent protection for semaglutide extends to 2032 in the US and 2033 in Europe and Japan, but the Canadian approval demonstrates that regulatory pathways for competitors exist well before those expiry dates.
The company’s response includes a new telehealth-driven subscription model for Wegovy, launched on March 31, 2026. Self-paying patients can now access structured multi-month plans through platforms including Ro, WeightWatchers, and LifeMD, with Hims & Hers expected to join the network. The strategy aims to lock in patient loyalty before cheaper alternatives gain traction. Whether this model can sustain revenue growth as generics compress pricing in additional G7 markets remains the central question for investors.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The stock has staged a notable recovery from its March low of €30.25, climbing roughly 44 percent to trade near €43.47. That places it about 7.4 percent above its 50-day moving average of €40.47, with a relative strength index of 57.6 suggesting moderate upward momentum without overheating. The 200-day moving average sits at €40.37, a level that bulls view as critical support.
But the longer-term picture tells a different story. The shares remain roughly 27 percent below the 52-week high of €59.56 reached in July 2025, and the trailing twelve-month decline exceeds 27 percent. The gap between the recent rally and the sustained downtrend reflects genuine uncertainty about whether the recovery is sustainable.
Analyst opinions are sharply divided. Willow Tree Research initiated coverage with a buy rating and a $68 price target, citing the oral Wegovy pill — which received EU approval on July 15 — along with the pipeline including high-dose Wegovy, CagriSema, and Zenagamtide. The OASIS study showed the 25-milligram oral dose produced 17 percent weight loss versus 3 percent for placebo. A contrasting view rates the stock only a hold, pointing to a 10.3 percent year-over-year decline in adjusted revenue driven by weakness in Ozempic and Rybelsus, with no near-term pipeline catalysts to reverse the trend. Goldman Sachs cut its price target in March from 400 to 260 Danish kroner.
The company’s own guidance underscores the pressure: Novo Nordisk has forecast a 5 to 13 percent revenue decline for 2026, citing US price reductions, patent expirations, and intensifying competition from Eli Lilly and others. The next major test arrives on August 5, when the company reports quarterly earnings. That report will reveal whether the subscription model and telehealth partnerships are stabilizing margins — or whether generic erosion in international markets is already weighing on top-line growth.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from July 27 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 27.
Novo Nordisk: Buy or sell? Read more here...
